Invest. Engage. Save.

Rss

Don't Blame the Market

Posted by: BIO Ventures for Global Health on 5/3/2010
In a keynote luncheon address at the Partnering for Global Health Forum, Dr. Nils Daulaire, Director of Office of Global Health Affairs at the U.S. Dept. of Health and Human Services, reflected on the Obama Administration's commitments to global health and the critical needs that might be addressed by the biotech community.

"The Obama administration has decided that the issues of global health are important not just for humanitarian reasons, but for reasons of international security and for the health and well-being of the American people," Daulaire said. "In my new post at a domestic agency, we see global health as a necessary component of that well-being."

Dr. Daulaire also spoke about shifting away from the idea of 'market failure' in global health. "We are not looking at failure, but rather the natural workings of the market, where you have customers who cannot afford to purchase. Rather than talk about failure, we must talk about market limitation and ways to get around limitations with perhaps something more than the invisible hand.

"None of us assumes innovation and research comes from bureaucrats in Washington," he added. "It comes from people like you. "We have to be more open than the US government has ever been to look at ways that go outside the box. Progress has been far too little and far too slow."

"If we give the world the tools that it needs, we will need all of you to work with us, to press us, to nag us, to make sure we get the practical needs to apply those tools to the people who need it most."
Categories: Meetings News Partnering
Create a trackback from your own site.
|   Blog Home

0 Comments

Leave A Comment

Please enter the CAPTCHA phrase above.
 

  
  

Recent Comments

by Mark H on Trademark of Innovation
"Often the pharmaceutical companies are seen as evil because they do not do enough to help the poor by giving away medicines or licence rights. But we must consider two things: 1 they are commecial companies and have legal obligations towards their shareholders i.e. their prime concern is making money 2 these companies invest a vastly greater amount of money in R&D than the government. As a result their R&D occasionally finds cures inadvertently for other diseases - even if they are not actively trying to create the right medicine. So how do you create an incentive for the most effective creator of new innovative cures whose primary goal is to make money (like all companies)? Well the answer seems obvious - reward them with tax benefits that would help push them above their competitors. Whilst you could argue that this would prevent the government from reaping the benefits (tax) you could also say that the competition created would drive innovation and spending in the private sector which would improve the economy. A win win win situation - pharmaceuticals, government, developing countries!" Read more »

by BIO Ventures for Global Health on Ready to Go
"Thanks so much for your interest, Trudy. We are not currently working with the Carter Center but we are interested in speaking with them to gain epidemiological information for our Global Health Primer, and so hope to be working together in the future. " Read more »

by forex online trading on Speed Dating to Save Lives
"This is really nice and interesting blog.I m glad to know. I admire the time and effort you put into your blog and detailed information you offer. " Read more »

  

Tag Cloud